Lung Cancer Trials Ask AI to find trials
TerminatedNot applicableNCT01946100
Official study title

Treatment of Multifocal Lung Adenocarcinoma

Study summary

To gather preliminary safety and outcome data for the multimodality treatment of lung adenocarcinoma in the setting of multifocal BAC.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedMultifocal Lung Adenocarcinoma

The study team can explain what participation involves.

Who it may be forLung Neoplasms · Carcinoma Non-small-cell Lung

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Nov 20, 2025 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Mayo Clinic

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Not applicable
Sponsor
Mayo Clinic
Interventions being studied
Genetic: Multifocal Lung Adenocarcinoma
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Patient must be \> 18 years of age
  • Two or more GGO's or solid lesions suspicious for multifocal disease.
  • Clinical diagnosis of N0
  • No evidence of distant metastases
  • No prior intra-thoracic radiation therapy (NOTE: Previous radiotherapy as part of treatment for head and neck, breast, or other non-thoracic cancer is permitted.), previous chemotherapy, or surgical resection for non-small cell lung cancer (NSCLC).
  • No other cancer in the past 5 years except early stage prostate cancer, or basal cell of skin.
  • PFT's that show patient is capable of tolerating a lung resection.
  • Non-pregnant and non-lactating. Women of child-bearing potential must have a negative urine or serum pregnancy test to participate in the study.
  • Patient must be able to understand and willing to sign an IRB-approved informed consent document.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Mayo Clinic in RochesterRochester, Minnesota

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 20, 2025. Always confirm current availability with the study team.

View original record ↗